Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 393,044,832
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 12,255 M
  • Annual Income, $ -12,121,000 K
  • 36-Month Beta 0.59
  • Price/Sales 5.10
  • Price/Cash Flow 15.19
  • Price/Book 6.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.95
  • Number of Estimates 7
  • High Estimate 1.97
  • Low Estimate 1.93
  • Prior Year 1.74
  • Growth Rate Est. (year over year) +12.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
139.66 +5.33%
on 11/27/18
148.99 -1.27%
on 12/04/18
+1.48 (+1.02%)
since 11/12/18
3-Month
132.23 +11.25%
on 10/12/18
148.99 -1.27%
on 12/04/18
+7.74 (+5.55%)
since 09/12/18
52-Week
118.62 +24.01%
on 05/29/18
148.99 -1.27%
on 12/04/18
+4.50 (+3.16%)
since 12/12/17

Most Recent Stories

More News
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $147.10, marking a +0.41% move from the previous day.

JNJ : 147.10 (+0.41%)
Watch for Johnson&Johnson to Potentially Pullback After Gaining 1.21% Yesterday

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $147.00 to a high of $148.48. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

JNJ : 147.10 (+0.41%)
Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya

The CHMP postpones the review timeline of Portola's (PTLA) Ondexxya (in the EU. Shares take a hit.

JNJ : 147.10 (+0.41%)
HKMPF : 24.0000 (-9.08%)
PTLA : 21.57 (+10.62%)
BSTC : 61.53 (+0.67%)
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA® (guselkumab) was superior to Cosentyx® (secukinumab)* in treating...

JNJ : 147.10 (+0.41%)
Markets Right Now: Stock market ends mixed after a bumpy day

NEW YORK (AP) — The latest on developments in financial markets (all times local):

JNJ : 147.10 (+0.41%)
Vect-Horus Announces Agreement With Johnson & Johnson Innovation

Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration...

JNJ : 147.10 (+0.41%)
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800

Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.

JNJ : 147.10 (+0.41%)
LLY : 114.34 (-0.14%)
ABBV : 88.60 (+0.49%)
BMY : 53.44 (+1.93%)
Former Johnson & Johnson Chairman and CEO, William C. Weldon, to Receive 2019 Horatio Alger Award

Horatio Alger Association of Distinguished Americans, Inc., a nonprofit educational organization honoring the achievements of outstanding individuals and encouraging youth to pursue their dreams through...

JNJ : 147.10 (+0.41%)
Quotient Technology Drives Results for Johnson & Johnson's Entire Aveeno Portfolio Using Digital Promotions, Media and Analytics

For years, Johnson & Johnson has used promotions to help launch products and drive sales. For the Aveeno brand, J&J was looking to increase market penetration and sales of its entire Aveeno...

JNJ : 147.10 (+0.41%)
QUOT : 12.46 (+2.55%)
WhiteSwell Announces $30 Million Financing for New Therapeutic Approach to Acute Decompensated Heart Failure

WhiteSwell, a company pioneering new ways to treat acute decompensated heart failure, today announced the close of a $30 million series B funding round led by RA Capital Management and an...

JNJ : 147.10 (+0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 149.02
1st Resistance Point 148.06
Last Price 147.10
1st Support Level 146.57
2nd Support Level 146.04

See More

52-Week High 148.99
Last Price 147.10
Fibonacci 61.8% 137.39
Fibonacci 50% 133.81
Fibonacci 38.2% 130.22
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar